This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Damond, F.
Right arrow Articles by Descamps, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Damond, F.
Right arrow Articles by Descamps, D.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, January 2005, p. 484-487, Vol. 43, No. 1
0095-1137/05/$08.00+0     doi:10.1128/JCM.43.1.484-487.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Polymorphism of the Human Immunodeficiency Virus Type 2 (HIV-2) Protease Gene and Selection of Drug Resistance Mutations in HIV-2-Infected Patients Treated with Protease Inhibitors

F. Damond,1,2 F. Brun-Vezinet,1,2 S. Matheron,1 G. Peytavin,1 P. Campa,1 S. Pueyo,3 F. Mammano,2 S. Lastere,1,2 I. Farfara,1 F. Simon,4 G. Chene,3 and D. Descamps1,2*

Hôpital Bichat-Claude Bernard,1 INSERM U552, Paris,3 INSERM U330, Bordeaux, France,2 Institut Pasteur, Dakar, Senegal4

Received 8 November 2003/ Returned for modification 12 March 2004/ Accepted 12 September 2004

We described the baseline polymorphism of the human immunodeficiency virus type 2 (HIV-2) protease gene from 94 treatment-naive patients and the longitudinal follow-up of 17 protease inhibitor-treated patients. Compared to the HIV-2 consensus sequences, baseline polymorphism involved 47 positions. Substitutions selected under treatment were observed at positions corresponding to HIV-1 resistance mutations as well as at positions of currently unknown impact on HIV-1.

* Corresponding author. Mailing address: Laboratoire de Virologie, Hôpital Bichat-Claude Bernard, 46 rue Henri Huchard, 75018 Paris, France. Phone: 33 1 40 25 61 54. Fax: 33 1 40 25 67 69. E-mail: diane.descamps{at}bch.ap-hop-paris.fr.

Journal of Clinical Microbiology, January 2005, p. 484-487, Vol. 43, No. 1
0095-1137/05/$08.00+0     doi:10.1128/JCM.43.1.484-487.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Ntemgwa, M. L., Toni, T. d., Brenner, B. G., Camacho, R. J., Wainberg, M. A. (2009). Antiretroviral Drug Resistance in Human Immunodeficiency Virus Type 2. Antimicrob. Agents Chemother. 53: 3611-3619 [Full Text]  
  • Jallow, S., Alabi, A., Sarge-Njie, R., Peterson, K., Whittle, H., Corrah, T., Jaye, A., Cotten, M., Vanham, G., McConkey, S. J., Rowland-Jones, S., Janssens, W. (2009). Virological Response to Highly Active Antiretroviral Therapy in Patients Infected with Human Immunodeficiency Virus Type 2 (HIV-2) and in Patients Dually Infected with HIV-1 and HIV-2 in The Gambia and Emergence of Drug-Resistant Variants. J. Clin. Microbiol. 47: 2200-2208 [Abstract] [Full Text]  
  • Desbois, D., Roquebert, B., Peytavin, G., Damond, F., Collin, G., Benard, A., Campa, P., Matheron, S., Chene, G., Brun-Vezinet, F., Descamps, D., for the French ANRS HIV-2 Cohort (ANRS CO 05 VIH-2, (2008). In Vitro Phenotypic Susceptibility of Human Immunodeficiency Virus Type 2 Clinical Isolates to Protease Inhibitors. Antimicrob. Agents Chemother. 52: 1545-1548 [Abstract] [Full Text]  
  • Ntemgwa, M., Brenner, B. G., Oliveira, M., Moisi, D., Wainberg, M. A. (2007). Natural Polymorphisms in the Human Immunodeficiency Virus Type 2 Protease Can Accelerate Time to Development of Resistance to Protease Inhibitors. Antimicrob. Agents Chemother. 51: 604-610 [Abstract] [Full Text]  
  • Rodes, B., Sheldon, J., Toro, C., Jimenez, V., Alvarez, M. A., Soriano, V. (2006). Susceptibility to protease inhibitors in HIV-2 primary isolates from patients failing antiretroviral therapy. J Antimicrob Chemother 57: 709-713 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»